Related Experiment Videos
[The best of thrombosis in 2002]
1Service de cardiologie A, hôpital Trousseau 37044 Tours.
Insights
The CADILLAC study reignited discussions on glycoprotein IIb/IIIa inhibitors during acute myocardial infarction. New thrombolysis methods and comparisons between angioplasty and lysis are under evaluation.
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Coronary Syndromes
Background:
- The CADILLAC study has prompted a re-evaluation of glycoprotein IIb/IIIa inhibitor use in acute myocardial infarction.
- Ongoing research explores novel thrombolysis strategies and compares percutaneous coronary intervention (PCI) with fibrinolysis.
Purpose of the Study:
- To review recent advancements and ongoing debates in the management of myocardial infarction and related cardiovascular conditions.
- To highlight key studies comparing different treatment modalities and their implications for clinical practice.
Main Methods:
- Review of significant clinical trials including CADILLAC, INTRO-AMI, TIMI 23, STOPAMI 2, CAPTIM, and RITA 3.
- Analysis of updated clinical recommendations and emerging research on therapeutic interactions and risk factors.
Main Results:
- The CADILLAC study supports the systematic use of glycoprotein IIb/IIIa inhibitors with primary angioplasty.
- Studies comparing angioplasty and lysis show varying outcomes, with interventional approaches often favored (e.g., RITA 3 for unstable angina).
- Research is evaluating new thrombolysis combinations and risk factors for cerebrovascular accidents.
Conclusions:
- Percutaneous coronary intervention, particularly with glycoprotein IIb/IIIa inhibitors, is increasingly favored in acute myocardial infarction and unstable angina.
- Further research is needed to optimize thrombolysis strategies and understand risk factors for cardiovascular events.
Abstract:
In the area of myocardial infarction one is reminded of the publication of the CADILLAC study which has reopened the debate on the systematic use of GpIIbIIIa inhibitors in the acute phase of myocardial infarction complementing primary angioplasty with the placement of an endoprosthesis. New modalities for thrombolysis are in the course of evaluation, notably Eptibaphide Alteplase combination in the INTRO-AMI study and Tenecteplase Abciximab in association with enoxaparine or non-fractionated heparin in the TIMI 23 study. Several studies comparing angioplasty to lysis have been published. STOPAMI 2 evaluated myocardial salvage in the framework of primary angioplasty with placement of an endoprosthesis combined with abciximab infusion in comparison with half dose fibrinolysis associated with abciximab. CAPTIM is a strategy evaluation comparing the results of pre-hospital fibrinolysis with primary angioplasty. With the RITA 3 study the interventional approach definitely comes top in comparison with a conservative approach for the treatment of unstable angina. One is equally reminded of the changes in the ACC/AHA recommendations for the management of unstable angina. The debate continues on the indications for thrombolysis in submassive pulmonary embolus. In the therapeutic area, one is reminded of the update on the interactions between angiotensin converting enzymes and aspirin in treatment and long term coronary syndrome. Finally, at the end of 2001, the work of French teams was published concerning the evaluation of risk of relapse for cerebral vascular accident in the presence of a foramen ovale or an aneurysm of the inter-atrial septum.